Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 363278, 11 pages
http://dx.doi.org/10.1155/2015/363278
Review Article

Red Blood Cell Destruction in Autoimmune Hemolytic Anemia: Role of Complement and Potential New Targets for Therapy

1Department of Medicine, Haugesund Hospital, Helse Fonna, P.O. Box 2170, 5504 Haugesund, Norway
2Department of Immunology and Transfusion Medicine, Haugesund Hospital, Helse Fonna, P.O. Box 2170, 5504 Haugesund, Norway

Received 25 June 2014; Revised 6 November 2014; Accepted 10 November 2014

Academic Editor: Jerome Moreaux

Copyright © 2015 Sigbjørn Berentsen and Tatjana Sundic. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Dacie, “The auto-immune haemolytic anaemias: introduction,” in The Haemolytic Anaemias, J. Dacie, Ed., vol. 3, pp. 1–5, Churchill Livingstone, London, UK, 1992. View at Google Scholar
  2. R. J. Sokol, S. Hewitt, and B. K. Stamps, “Autoimmune haemolysis: an 18-year study of 865 cases referred to a regional transfusion centre,” British Medical Journal, vol. 282, no. 6281, pp. 2023–2027, 1981. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Michel, “Classification and therapeutic approaches in autoimmune hemolytic anemia: an update,” Expert Review of Hematology, vol. 4, no. 6, pp. 607–618, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. C. H. Packman, “Hemolytic anemia due to warm autoantibodies,” Blood Reviews, vol. 22, no. 1, pp. 17–31, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Berentsen and G. E. Tjønnfjord, “Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia,” Blood Reviews, vol. 26, no. 3, pp. 107–115, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Garratty, “The James Blundell Award Lecture 2007: do we really understand immune red cell destruction?” Transfusion Medicine, vol. 18, no. 6, pp. 321–334, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Dacie, “Auto-immune haemolytic anaemia (AIHA): pathogenesis,” in The Haemolytic Anaemias, J. Dacie, Ed., vol. 3, pp. 392–451, Churchill Livingstone, London, UK, 1992. View at Google Scholar
  8. S. Berentsen, K. Beiske, and G. E. Tjønnfjord, “Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy,” Hematology, vol. 12, no. 5, pp. 361–370, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. E. L. Larghi and T. S. Kaufman, “Modulators of complement activation: a patent review (2008–2013),” Expert Opinion on Therapeutic Patents, vol. 24, no. 6, pp. 665–686, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Shi, E. L. Rose, A. Singh et al., “TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinin disease patient autoantibodies,” Blood, vol. 123, no. 26, pp. 4015–4022, 2014. View at Publisher · View at Google Scholar
  11. S. Berentsen, “Complement, cold agglutinins, and therapy,” Blood, vol. 123, no. 26, pp. 4010–4012, 2014. View at Google Scholar
  12. A. Hill, R. P. Rother, L. Arnold et al., “Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization,” Haematologica, vol. 95, no. 4, pp. 567–573, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. B. C. Gehrs and R. C. Friedberg, “Autoimmune hemolytic anemia,” American Journal of Hematology, vol. 69, no. 4, pp. 258–271, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. L. F. Diehl and L. H. Ketchum, “Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia,” Seminars in Oncology, vol. 25, no. 1, pp. 80–97, 1998. View at Google Scholar · View at Scopus
  15. E. Fagiolo, “Immunological tolerance loss vs. erythrocyte self antigens and cytokine network disregulation in autoimmune hemolytic anaemia,” Autoimmunity Reviews, vol. 3, no. 2, pp. 53–59, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. F. J. Ward, A. M. Hall, L. S. Cairns et al., “Clonal regulatory T cells specific for a red blood cell autoantigen in human autoimmune hemolytic anemia,” Blood, vol. 111, no. 2, pp. 680–687, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. P. C. Hoffman, “Immune hemolytic anemia—selected topics,” Hematology. American Society of Hematology. Education Program, pp. 13–18, 2006. View at Google Scholar
  18. D. Janvier, F. Sellami, F. Missud et al., “Severe autoimmune hemolytic anemia caused by a warm IgA autoantibody directed against the third loop of band 3 (RBC anion-exchange protein 1).,” Transfusion, vol. 42, no. 12, pp. 1547–1552, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. P. A. Arndt, R. M. Leger, and G. Garratty, “Serologic findings in autoimmune hemolytic anemia associated with immunoglobulin M warm autoantibodies,” Transfusion, vol. 49, no. 2, pp. 235–242, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Zeerleder, “Autoimmune haemolytic anaemia—a practical guide to cope with a diagnosticand therapeutic challenge,” Netherlands Journal of Medicine, vol. 69, no. 4, pp. 177–184, 2011. View at Google Scholar · View at Scopus
  21. U. J. H. Sachs, L. Röder, S. Santoso, and G. Bein, “Does a negative direct antiglobulin test exclude warm autoimmune haemolytic anaemia? A prospective study of 504 cases,” British Journal of Haematology, vol. 132, no. 5, pp. 655–656, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Gilsanz, J. de La Serna, L. Moltó, and M. Alvarez-Mon, “Hemolytic anemia in chronic large granular lymphocytic leukemia of natural killer cells: cytotoxicity of natural killer cells against autologous red cells is associated with hemolysis,” Transfusion, vol. 36, no. 5, pp. 463–466, 1996. View at Publisher · View at Google Scholar · View at Scopus
  23. H. L. Griffiths, B. M. Kumpel, C. J. Elson, and A. G. Hadley, “The functional activity of human monocytes passively sensitized with monoclonal anti-D suggests a novel role for FcγRI in the immune destruction of blood cells,” Immunology, vol. 83, no. 3, pp. 370–377, 1994. View at Google Scholar · View at Scopus
  24. M. Lai, G. Leone, and R. Landolfi, “Autoimmune hemolytic anemia with gel-based immunohematology tests,” American Journal of Clinical Pathology, vol. 139, no. 4, pp. 457–463, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. J. H. Jandl, A. R. Jones, and W. B. Castle, “The destruction of red cells by antibodies in man. I. Observations of the sequestration and lysis of red cells altered by immune mechanisms,” The Journal of Clinical Investigation, vol. 36, no. 10, pp. 1428–1459, 1957. View at Publisher · View at Google Scholar · View at Scopus
  26. J. H. Jandl and M. E. Kaplan, “The destruction of red cells by antibodies in man. III. Quantitative factors influencing the patterns of hemolysis in vivo,” The Journal of Clinical Investigation, vol. 39, pp. 1145–1156, 1960. View at Google Scholar · View at Scopus
  27. R. J. Kurlander and W. F. Rosse, “Monocyte-mediated destruction in the presence of serum of red cells coated with antibody,” Blood, vol. 54, no. 5, pp. 1131–1139, 1979. View at Google Scholar · View at Scopus
  28. A. F. Lobuglio, R. S. Cotran, and J. H. Jandl, “Red cells coated with immunoglobulin G: binding and sphering by mononuclear cells in man,” Science, vol. 158, no. 3808, pp. 1582–1585, 1967. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Abramson, A. F. Lo Buglio, J. H. Jandl, and R. S. Cotran, “The interaction between human monocytes and red cells. Binding characteristics,” The Journal of Experimental Medicine, vol. 132, no. 6, pp. 1191–1206, 1970. View at Publisher · View at Google Scholar · View at Scopus
  30. E. M. Meulenbroek, D. Wouters, and S. Zeerleder, “Methods for quantitative detection of antibody-induced complement activation on red blood cells,” Journal of Visualized Experiments, no. 83, Article ID e51161, 2014. View at Publisher · View at Google Scholar
  31. R. J. Kurlander, W. F. Rosse, and G. L. Logue, “Quantitative influence of antibody and complement coating of red cells on monocyte-mediated cell lysis,” The Journal of Clinical Investigation, vol. 61, no. 5, pp. 1309–1319, 1978. View at Publisher · View at Google Scholar · View at Scopus
  32. A. D. Schreiber and M. M. Frank, “Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing sites,” The Journal of Clinical Investigation, vol. 51, no. 3, pp. 575–582, 1972. View at Publisher · View at Google Scholar · View at Scopus
  33. N. Abramson, E. W. Gelfand, J. H. Jandl, and F. S. Rosen, “The interaction between human monocytes and red cells. Specificity for IgG subclasses and IgG fragments,” The Journal of Experimental Medicine, vol. 132, no. 6, pp. 1207–1215, 1970. View at Publisher · View at Google Scholar · View at Scopus
  34. Z. Li, Z. Shao, Y. Xu et al., “Subclasses of warm autoantibody IgG in patients with autoimmune hemolytic anemia and their clinical implications,” Chinese Medical Journal, vol. 112, no. 9, pp. 805–808, 1999. View at Google Scholar · View at Scopus
  35. B. Bardill, C. Mengis, M. Tschopp, and W. A. Wuillemin, “Severe IgA-mediated auto-immune haemolytic anaemia in a 48-yr-old woman,” European Journal of Haematology, vol. 70, no. 1, pp. 60–63, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Birgens, H. Frederiksen, H. C. Hasselbalch et al., “A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia,” British Journal of Haematology, vol. 163, no. 3, pp. 393–399, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Zanella and W. Barcellini, “Treatment of autoimmune hemolytic anemias,” Hematology Education: The Education Program for the Annual Congress of the European Hematology Association, vol. 8, pp. 339–348, 2014. View at Google Scholar
  38. S. Berentsen, “Rituximab for the treatment of autoimmune cytopenias,” Haematologica, vol. 92, no. 12, pp. 1589–1596, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. L. D. Petz and G. Garratty, “Management of autoimmune hemolytic anemias,” in Immune Hemolytic Anemias, L. D. Petz and G. Garratty, Eds., pp. 401–458, Churchill Livingstone, Philadelphia, Pa, USA, 2004. View at Google Scholar
  40. G. K. Melve, T. Hervig, R. Øvrebøe, and I. Nesthus, “Blood transfusion and pretransfusion testing in patients with warm autoimmune haemolytic anaemia,” Tidsskrift for den Norske Laegeforening, vol. 124, no. 22, pp. 2918–2920, 2004 (Norwegian). View at Google Scholar · View at Scopus
  41. R. S. Shirey, J. S. Boyd, A. V. Parwani, W. S. Tanz, P. M. Ness, and K. E. King, “Prophylactic antigen-matched donor blood for patients with warm autoantibodies: an algorithm for transfusion management.,” Transfusion, vol. 42, no. 11, pp. 1435–1441, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Meny, “Review: transfusing incompatible RBCs: clinical aspects,” Immunohematology, vol. 20, no. 3, pp. 161–166, 2004. View at Google Scholar · View at Scopus
  43. L. D. Petz, “A physician's guide to transfusion in autoimmune haemolytic anaemia,” British Journal of Haematology, vol. 124, no. 6, pp. 712–716, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. U. Randen, G. Troen, A. Tierens et al., “Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma,” Haematologica, vol. 99, no. 3, pp. 497–504, 2014. View at Google Scholar
  45. S. Berentsen, E. Ulvestad, R. Langholm et al., “Primary chronic cold agglutinin disease: a population based clinical study of 86 patients,” Haematologica, vol. 91, no. 4, pp. 460–466, 2006. View at Google Scholar · View at Scopus
  46. W. F. Rosse and J. P. Adams, “The variability of hemolysis in the cold agglutinin syndrome,” Blood, vol. 56, no. 3, pp. 409–416, 1980. View at Google Scholar · View at Scopus
  47. M. Harboe and J. Deverill, “Immunochemical properties of cold haemagglutinins,” Scandinavian Journal of Haematology, vol. 61, pp. 223–237, 1964. View at Google Scholar · View at Scopus
  48. C. T. Hughey, J. W. Brewer, A. D. Colosia, W. F. Rosse, and R. B. Corley, “Production of IgM hexamers by normal and autoimmune B cells: implications for the physiologic role of hexameric IgM,” Journal of Immunology, vol. 161, no. 8, pp. 4091–4097, 1998. View at Google Scholar · View at Scopus
  49. M. J. Stone, Y. G. McElroy, A. Pestronk, J. L. Reynolds, J. T. Newman, and A. W. Tong, “Human monoclonal macroglobulins with antibody activity,” Seminars in Oncology, vol. 30, no. 2, pp. 318–324, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Harboe, R. van Furth, H. Schubothe, K. Lind, and R. S. Evans, “Exclusive occurrence of K chains in isolated cold haemagglutinins,” Scandinavian Journal of Haematology, vol. 2, no. 3, pp. 259–266, 1965. View at Google Scholar · View at Scopus
  51. P. L. Swiecicki, L. T. Hegerova, and M. A. Gertz, “Cold agglutinin disease,” Blood, vol. 122, no. 7, pp. 1114–1121, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. S. P. Treon, L. Xu, G. Yang et al., “MYD88 L265P somatic mutation in Waldenström's macroglobulinemia,” The New England Journal of Medicine, vol. 367, no. 9, pp. 826–833, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. A. S. Wiener, L. J. Unger, L. Cohen, and J. Feldman, “Type-specific cold auto-antibodies as a cause of acquired hemolytic anemia and hemolytic transfusion reactions: biologic test with bovine red cells,” Annals of internal medicine, vol. 44, no. 2, pp. 221–240, 1956. View at Publisher · View at Google Scholar · View at Scopus
  54. P. D. Issitt, “I blood group system and its relationship to disease,” The Journal of Medical Laboratory Technology, vol. 25, no. 1, pp. 1–6, 1968. View at Google Scholar · View at Scopus
  55. E. Ulvestad, S. Berentsen, K. Bø, and F. V. Shammas, “Clinical immunology of chronic cold agglutinin disease,” European Journal of Haematology, vol. 63, no. 4, pp. 259–266, 1999. View at Google Scholar · View at Scopus
  56. J. Jonsen, E. Kass, and M. Harboe, “Complement and complement components in acquired hemolytic anemia with high titer cold antibodies,” Acta Medica Scandinavica, vol. 170, pp. 725–729, 1961. View at Google Scholar · View at Scopus
  57. C. J. Jaffe, J. P. Atkinson, and M. M. Frank, “The role of complement in the clearance of cold agglutinin sensitized erythrocytes in man,” Journal of Clinical Investigation, vol. 58, no. 4, pp. 942–949, 1976. View at Publisher · View at Google Scholar · View at Scopus
  58. E. Ulvestad, S. Berentsen, and T. E. Mollnes, “Acute phase haemolysis in chronic cold agglutinin disease,” Scandinavian Journal of Immunology, vol. 54, no. 1-2, pp. 239–242, 2001. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Röth, A. Hüttmann, R. P. Rother, U. Dührsen, and T. Philipp, “Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease,” Blood, vol. 113, no. 16, pp. 3885–3886, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. E. Ulvestad, “Paradoxical haemolysis in a patient with cold agglutinin disease,” European Journal of Haematology, vol. 60, no. 2, pp. 93–100, 1998. View at Google Scholar · View at Scopus
  61. J. Dacie, “Auto-immune haemolytic anaemia (AIHA): treatment,” in The Haemolytic Anaemias, J. Dacie, Ed., vol. 3, pp. 452–520, Churchill Livingstone, London, UK, 1992. View at Google Scholar
  62. S. Berentsen, E. Ulvestad, and G. E. Tjønnfjord, “B-lymphocytes as targets for therapy in chronic cold agglutinin disease,” Cardiovascular & Hematological Disorders: Drug Targets, vol. 7, no. 3, pp. 219–227, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Berentsen, E. Ulvestad, B. T. Gjertsen et al., “Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients,” Blood, vol. 103, no. 8, pp. 2925–2928, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. C. Schollkopf, L. Kjeldsen, O. W. Bjerrum et al., “Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients,” Leukemia and Lymphoma, vol. 47, no. 2, pp. 253–260, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Ghielmini, S.-F. H. Schmitz, S. B. Cogliatti et al., “Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule,” Blood, vol. 103, no. 12, pp. 4416–4423, 2004. View at Publisher · View at Google Scholar · View at Scopus
  66. N. Cooper and D. M. Arnold, “The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases,” British Journal of Haematology, vol. 149, no. 1, pp. 3–13, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Berentsen, U. Randen, A. M. Vågan et al., “High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease,” Blood, vol. 116, no. 17, pp. 3180–3184, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. K. R. Carson, L. G. Beckwith, and J. Mehta, “Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib,” Blood, vol. 115, no. 4, p. 915, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Gueli, D. Gottardi, H. Hu, I. Ricca, A. de Crescenzo, and C. Tarella, “Efficacy of rituximab-bendamustine in cold agglutinin haemolytic anaemia refractory to previous chemo-immunotherapy: a case report,” Blood Transfusion, vol. 11, no. 2, pp. 311–314, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. S. Berentsen, “How I manage cold agglutinin disease,” British Journal of Haematology, vol. 153, no. 3, pp. 309–317, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. D. Crisp and W. Pruzanski, “B-cell neoplasms with homogeneous cold-reacting antibodies (cold agglutinins),” The American Journal of Medicine, vol. 72, no. 6, pp. 915–922, 1982. View at Publisher · View at Google Scholar · View at Scopus
  72. F. NíÁinle, O.-P. R. Hamnvik, C. Gulmann et al., “Diffuse large B-cell lymphoma with isolated bone marrow involvement presenting with secondary cold agglutinin disease,” International Journal of Laboratory Hematology, vol. 30, no. 5, pp. 444–445, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. A. E. Eskazan, H. Akmurad, S. Ongoren, O. Ozer, and B. Ferhanoglu, “Primary gastrointestinal diffuse large B cell lymphoma presenting with cold agglutinin disease,” Case Reports in Gastroenterology, vol. 5, no. 2, pp. 262–266, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. J. Dacie, “Haemolytic anaemias associated with malignant lymphomas other than Hodgkin's disease and chronic lymphocytic leukaemia (CLL),” in The Haemolytic Anaemias, J. Dacie, Ed., vol. 4, pp. 27–40, Churchill Livingstone, London, UK, 1995. View at Google Scholar
  75. D. H. Linz, S. W. Tolle, and D. L. Elliot, “Mycoplasma pneumoniae pneumonia. Experience at a referral center,” Western Journal of Medicine, vol. 140, no. 6, pp. 895–900, 1984. View at Google Scholar · View at Scopus
  76. H. S. Ginsberg, “Acute hemolytic anemia in primary atypical pneumonia associated with high titer of cold agglutinins; report of a case,” The New England Journal of Medicine, vol. 234, pp. 234–826, 1946. View at Publisher · View at Google Scholar
  77. P. Wentworth and L. R. Bate, “Acute hemolytic anemia secondary to infectious mononucleosis.,” Canadian Medical Association journal, vol. 123, no. 6, pp. 482–486, 1980. View at Google Scholar · View at Scopus
  78. J. Donath and K. Landsteiner, “Über Paroxysmale Hämoglobinurie,” Münchener medizinische Wochenschrift, vol. 51, pp. 1590–1593, 1904. View at Google Scholar
  79. M. A. Gertz, “Cold hemolytic syndrome,” Hematology/The Education Program of the American Society of Hematology, pp. 19–23, 2006. View at Google Scholar
  80. A. Ziman, R. Hsi, and D. Goldfinger, “Donath-Landsteiner antibody-associated hemolytic anemia after Haemophilus influenzae infection in a child,” Transfusion, vol. 44, no. 8, pp. 1127–1128, 2004. View at Publisher · View at Google Scholar · View at Scopus
  81. M. D'Angio, T. Ceglie, G. Giovannetti et al., “Visceral leishmaniasis presenting with paroxysmal cold haemoglobinuria,” Blood Transfusion, vol. 12, supplement 1, pp. s141–s143, 2014. View at Publisher · View at Google Scholar · View at Scopus
  82. B. Mayer, S. Yürek, H. Kiesewetter, and A. Salama, “Mixed-type autoimmune hemolytic anemia: differential diagnosis and a critical review of reported cases,” Transfusion, vol. 48, no. 10, pp. 2229–2234, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. T. A. Shah, C. T. Mauriello, P. S. Hair et al., “Complement inhibition significantly decreases red blood cell lysis in a rat model of acute intravascular hemolysis,” Transfusion, vol. 54, no. 11, pp. 2892–2900, 2014. View at Publisher · View at Google Scholar
  84. K. Bork, I. Steffensen, and T. Machnig, “Treatment with C1-esterase inhibitor concentrate in type I or II hereditary angioedema: a systematic literature review,” Allergy and Asthma Proceedings, vol. 34, no. 4, pp. 312–327, 2013. View at Publisher · View at Google Scholar · View at Scopus
  85. P. Hillmen, N. S. Young, J. Schubert et al., “The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria,” The New England Journal of Medicine, vol. 355, no. 12, pp. 1233–1243, 2006. View at Publisher · View at Google Scholar · View at Scopus
  86. A. M. Risitano, D. Ricklin, Y. Huang et al., “Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria,” Blood, vol. 123, no. 13, pp. 2094–2101, 2014. View at Publisher · View at Google Scholar · View at Scopus
  87. D. Wouters, F. Stephan, P. Strengers et al., “C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia,” Blood, vol. 121, no. 7, pp. 1242–1244, 2013. View at Publisher · View at Google Scholar · View at Scopus